Joint Clinical Trials Office

You are here

A Phase 2, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma

Clinical Trial Details

This clinical trial is for men and women with unresectable glioblastoma or gliosarcoma at first or second recurrence.

Currently available treatments for these disease groups are not very effective. The combination of DNX-2401 and pembrolizumab could enhance the efficacy of treatment against these aggressive brain tumors.

Participants on this trial will receive a single dose of DNX-2401 delivered intratumorally followed by sequential intravenous pembrolizumab every 3 weeks.

There is no potential for placebo on this trial. Participants will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.

Key Eligibility: 
  • Open to men and women age 18 and older
  • Diagnoses with glioblastoma or gliosarcoma at first or second recurrence
  • Participants must have unresectable disease
  • Detailed eligibility will be reviewed when you contact the study team

Study contact by location

Upper East Side - Manhattan


Andrea Zanello
(212) 746-1788

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:





Open to Enrollment

Age Group